Advanced glycation end products (AGEs)‐induced expression of TGF‐β1 is suppressed by a protease in the tubule cell line LLC‐PK1
Open Access
- 1 August 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 16 (8) , 1562-1569
- https://doi.org/10.1093/ndt/16.8.1562
Abstract
Background. Advanced glycation end products (AGEs) are assumed to play a key role in diabetic nephropathy (DN). Since little is known about their action in tubule cells, we investigated in LLC‐PK1 cells: (i) whether AGE‐bovine serum albumin (AGE‐BSA) affects cell proliferation and expression of transforming growth factor‐β (TGF‐β1); and (ii) whether the AGE‐induced effects can be modulated by trypsin due to interference with its binding proteins at the cell surface. Methods. Arrested cells were exposed to vehicle (control), AGE‐BSA (19–76 μM) and BSA (38 μM) in the presence or absence of trypsin (0.625–5.0 μg/ml) (2.5 μg/ml) for 24 h. We evaluated cell proliferation by cell count and by [3H]thymidine incorporation, TGF‐β1 expression by reverse transcription‐polymerase chain reaction (RT‐PCR), and TGF‐β1 protein by ELISA. In addition, cell accumulation of AGEs was studied by immunohistochemical staining of the AGE imidazolone. Results. AGE‐BSA inhibited [3H]thymidine incorporation, lowered cell number and increased cell protein content as well as TGF‐β1 mRNA and protein as compared with control and BSA. Immunohistochemical staining revealed a marked intracellular accumulation of the AGE imidazolone. Co‐incubation of AGE‐BSA with trypsin ameliorated the impaired thymidine incorporation, the decreased cell count and the enhanced cell protein content. TGF‐β1 overexpression was normalized, while TGF‐β1 protein declined insignificantly. Intracellular imidazolone accumulation was strikingly suppressed. Conclusions. In the tubule cell line LLC‐PK1, AGE‐BSA exerts an antiproliferative effect, most probably due to TGF‐β1 overproduction. The co‐administration of trypsin abrogated this alteration, very likely as a result of an interaction with AGE‐binding protein(s), which is supported by the decreased intracellular AGE accumulation. These findings may be the starting point for the development of specific proteolytic enzymes to interfere with the interaction between AGEs and their receptors/binding proteins.Keywords
This publication has 31 references indexed in Scilit:
- Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product bindingKidney International, 1999
- Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetesKidney International, 1998
- Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.Journal of Clinical Investigation, 1997
- What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucoseEuropean Journal of Clinical Investigation, 1997
- Advanced glycation end products modulate transcriptional regulation in mesangial cellsKidney International, 1996
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end productsKidney International, 1995
- Antioxidants Reverse the Antiproliferative Effect of High Glucose and Advanced Glycosylation End Products in Cultured Rat Mesangial CellsBiochemical and Biophysical Research Communications, 1994
- Structural-functional correlations of diabetic nephropathyKidney International, 1994
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988